171 related articles for article (PubMed ID: 19880049)
1. Chemotherapy and biologic therapies for melanoma: do they work?
Jilaveanu LB; Aziz SA; Kluger HM
Clin Dermatol; 2009; 27(6):614-25. PubMed ID: 19880049
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
Kim KB; Eton O; East MJ; Hodges C; Papadopoulos NE; Grimm EA; Bedikian AY
Cancer; 2004 Aug; 101(3):596-603. PubMed ID: 15274073
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
4. Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction.
Margolin KA
Cancer; 2004 Aug; 101(3):435-8. PubMed ID: 15274056
[No Abstract] [Full Text] [Related]
5. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of metastasized malignant melanoma].
Kamanabrou D
Praxis (Bern 1994); 2001 Mar; 90(10):391-6. PubMed ID: 11305184
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
Schmidt H; Suciu S; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; von der Maase H; Eggermont AM; Keilholz U; ;
J Clin Oncol; 2007 Apr; 25(12):1562-9. PubMed ID: 17443000
[TBL] [Abstract][Full Text] [Related]
8. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
10. [Prognostic factors and improving treatment of cutaneous melanoma].
Vihinen P; Kähäri VM; Pyrhönen S
Duodecim; 2004; 120(12):1445-56. PubMed ID: 15293705
[No Abstract] [Full Text] [Related]
11. Malignant melanoma.
Califano J; Nance M
Facial Plast Surg Clin North Am; 2009 Aug; 17(3):337-48. PubMed ID: 19698915
[TBL] [Abstract][Full Text] [Related]
12. Subcutaneous interleukin-2 and interferon-alpha therapy associated with cisplatin monochemotherapy in the treatment of metastatic melanoma.
Andrès P; Cupissol D; Guillot B; Avril MF; Drèno B
Eur J Dermatol; 1998 Jun; 8(4):235-9. PubMed ID: 9649695
[TBL] [Abstract][Full Text] [Related]
13. Metastatic melanoma: chemotherapy to biochemotherapy.
O'Day SJ; Kim CJ; Reintgen DS
Cancer Control; 2002; 9(1):31-8. PubMed ID: 11907464
[TBL] [Abstract][Full Text] [Related]
14. Treatment for metastatic malignant melanoma: old drugs and new strategies.
Mouawad R; Sebert M; Michels J; Bloch J; Spano JP; Khayat D
Crit Rev Oncol Hematol; 2010 Apr; 74(1):27-39. PubMed ID: 19781957
[TBL] [Abstract][Full Text] [Related]
15. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
16. Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
Lewis KD; Robinson WA; McCarter M; Pearlman N; O'Day SJ; Anderson C; Amatruda TT; Baron A; Zeng C; Becker M; Dollarhide S; Matijevich K; Gonzalez R
J Clin Oncol; 2006 Jul; 24(19):3157-63. PubMed ID: 16809738
[TBL] [Abstract][Full Text] [Related]
17. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
18. Biochemotherapy in patients with advanced head and neck mucosal melanoma.
Bartell HL; Bedikian AY; Papadopoulos NE; Dett TK; Ballo MT; Myers JN; Hwu P; Kim KB
Head Neck; 2008 Dec; 30(12):1592-8. PubMed ID: 18798304
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
20. Childhood melanoma.
Jen M; Murphy M; Grant-Kels JM
Clin Dermatol; 2009; 27(6):529-36. PubMed ID: 19880040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
